Results 131 to 140 of about 14,332 (282)

Leveraging artificial intelligence for evidence‐based recommendations in uterine fibroid therapy: Addressing the unmet need in German healthcare—A clinical trial

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To evaluate the potential of an artificial intelligence (AI)‐driven large language model, ChatGPT 4.0, to provide personalized, evidence‐based treatment recommendations for uterine fibroids. Methods ChatGPT 4.0 was trained using evidence‐based data from Uptodate and German medical literature.
Iason Psilopatis   +5 more
wiley   +1 more source

Cancer and fertility management: FIGO best practice advice

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Cancer diagnoses in patients of reproductive age require balancing urgent oncological treatment with the need to preserve fertility. This FIGO Best Practice Advice outlines key considerations for fertility management in this population given the rising cancer incidence among young women and the reproductive risks posed by cancer treatments ...
Nikhil Purandare   +28 more
wiley   +1 more source

Research and scholarly methods: Mitigating information bias

open access: yesJACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, EarlyView.
Abstract Whether designing a research study or considering changes to a patient's medication therapy based on published research, pharmacists must be knowledgeable about potential sources of bias in clinical research and how these threats to internal validity can be mitigated.
Gary L. Cochran   +2 more
wiley   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Fezolinetant is a non‐hormonal, selective neurokinin 3 receptor antagonist approved in multiple countries including the United States, in Europe, and in Asia for the treatment of moderate to severe vasomotor symptoms in menopausal women. Fezolinetant is primarily metabolized by CYP1A2 and was found to be a sensitive substrate for CYP1A2 ...
Mary P. Choules   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy